<DOC>
	<DOC>NCT00479349</DOC>
	<brief_summary>To assess the safety and tolerability of ascending multiple oral doses of SAM-531, an investigational drug, in healthy Japanese young male and elderly subjects.To provide the pharmacokinetics (PK) and pharmacodynamics (PD) profiles of multiple oral doses of SAM-531 in healthy Japanese young male and elderly subjects.</brief_summary>
	<brief_title>Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of SAM-531</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Inclusion criteria Men aged 20 to 45 years, inclusive, at screening. Elderly men or women aged 65 years and above as of screening. Body mass index (BMI) in the range of 17.6 to 26.4 kg/m2 and body weight â‰¥45 kg. Exclusion critereia Any significant cardiovascular, hepatic, renal, respiratory, gastrointestinal, endocrine, immunologic, dermatologic, hematologic, neurologic, or psychiatric disease. Any clinically important deviation from normal limits in physical examination, vital signs, 12lead ECGs, or clinical laboratory test results. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels should be below the upper limit of normal at screening. Tobacco use or consumption of any caffeinecontaining products (e.g., coffee, tea, chocolate, or carbonated beverages) or alcoholic beverages within 48 hours before study day 1 until the end of the inpatient confinement period.</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
</DOC>